Business
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with Aditxt ...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025\n\n\n\n\n Received overwhelming shareholder support in favour of take-private transaction with Aditxt\n \n\n\n\n Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Investigational New Drug submission\n \n\n\n\n Further strengthened government partnerships, reinforcing Appili’s position as a key player in biodefense and infectious disease solutions.\n \n\n\n HALIFAX, Nova Scotia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2025, which ended on December 31, 2024. All figures are in Canadian dollars unless otherwise stated.\n \n\n “As we move into 2025, I want to extend my deepest gratitude to our supporters and partners who have stood by us through both challenges and progress,” said Dr. Don Cilla, President and CEO of Appili. “The past year highlighted global concerns surrounding public health and biosecurity, reaffirming the urgent need for infectious disease solutions. With strong government partnerships, promising near-clinical stage programs, and a dedicated team, we are well-positioned to accelerate the development of critical infectious disease treatments.”\n \n\n “Building on our expanded government partnerships, and the commercial launch of LIKMEZ™, Appili continues to make significant strides in our pipeline programs targeting critical infectious diseases for which effective treatments are currently unavailable,” Dr. Cilla added. “This year, we will continue to outline the vital role these programs play in protecting patients and the value they bring to our stakeholders.”\n \n\n\n ATI-1701, our Biodefense Vaccine Candidate with Strong Government Support\n \n\n\n Appili’s ATI-1701 development program, focused on the prevention of\n \n Francisella tularensis\n \n infection, has secured awards totaling US$14 million from the U.S. Air Force Academy (“USAFA”). Under this cooperative agree...